• Savient Pharmaceuticals Inc., of East Brunswick, N.J., reported fourth-quarter 2011 revenues of $3.7 million and a net loss of $30.9 million, or 44 cents per share, a wider loss than the 38 cents per share analysts had predicted. For the full year, Savient reported a net loss of $102 million, or $1.46 per share. Sales of gout drug Krystexxa (pegloticase) grew to $3 million for the fourth quarter.